The treatment of diabetes mellitus of patients with chronic liver disease
Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 6
Abstract
About 80% of patients with liver cirrhosis may have glucose metabolism disorders, 30% show overt diabetes mellitus (DM). Prospective studies have demonstrated that DM is associated with an increased risk of hepatic complications and death in patients with liver cirrhosis. DM might contribute to liver damage by promoting inflammation and fibrosis through an increase in mitochondrial oxidative stress mediated by adipokines. Based on the above mentioned the effective control of hyperglycemia may have a favorable impact on the evolution of these patients. However, only few therapeutic studies have evaluated the effectiveness and safety of antidiabetic drugs and the impact of the treatment of DM on morbidity and mortality in patients with liver cirrhosis. In addition, oral hypoglycemic agents and insulin may produce hypoglycemia and lactic acidosis, as most of these agents are metabolized by the liver. This review discusses the clinical implications of DM in patients with chronic liver disease. In addition the effectiveness and safety of old, but particularly the new antidiabetic drugs will be described based on pharmacokinetic studies and chronic administration to patients. Recent reports regarding the use of the SGLT2 inhibitors as well as the new incretin-based therapies such as injectable glucagon-like peptide-1 (GLP-1) receptor agonists and oral inhibitors of dipeptidylpeptidase-4 (DPP-4) will be discussed. The establishment of clear guidelines for the management of diabetes in patients with CLD is strongly required.
Authors and Affiliations
Diego García-Compeán, José González-González, Fernando Lavalle-González, Emmanuel González-Moreno, Héctor Maldonado-Garza, Jesús Villarreal-Pérez
Keywords
Related Articles
- EP ID EP78508
- DOI 10.5604/16652681.1171746
- Views 110
- Downloads 0
Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico
Background and aim. To identify the geographic distribution of hepatitis C virus (HCV) genotypes and HCV RNA viral load in a large number of HCV-infected carriers in Mexico. Methods. Patients with chronic hepatitis C (n...
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/Afric...
title
abstrakt<br/><br/>
Annals Impact Factor 1.67. Welcome to the IF club: achievement and challeng
Portal vein thrombosis in patients with cirrhosis: just a common finding or a predictor of poor outcome?
Background &amp;amp; Aims. It is unclear whether portal vein thrombosis (PVT) unrelated to malignancy is associated with reduced survival or it is an epiphenomenon of advanced cirrhosis. The objective of this study...